Spring mating season starts for pharma

A new year, and brand new opportunities to grow the business. Bend Research is certainly on the receiving end of much activity. Our most recent update at the start of the year on the company (see the January 8 2013 LRTJ) saw its "Lux Take" upgraded from Positive to Strong Positive. This is attribute...

This research is archived and therefore no longer available. For further assistance please contact your Customer Success Manager or email ClientEngagementTeam@luxresearchinc.com. Thank you!

Related Research

Seed Health raises $40 million Series A for its synbiotic product

News Commentary | May 05, 2021

This Series A round was led by The Craftory, Artis Ventures, and Gisev. With this funding, the company is looking to expand its consumer health supplement globally as well as focus on clinical research and its digital health unit, following its recent acquisition of Auggi. Seed's therapeutic arm has... Not part of subscription

Singaporean precision medicine startup Hummingbird Bioscience nets $125 million in Series C funding led by Novo Holdings

News Commentary | May 24, 2021

This will further expand Hummingbird's proprietary Rational Antibody Discovery (RAD) platform for novel therapeutic monoclonal antibodies. The market for therapeutic antibodies is rapidly growing, as new drugs have been approved for treating various human diseases, including many cancers and ... Not part of subscription

Pfizer will acquire Trillium Therapeutics for $2.26 billion, seeking to further boost its capabilities in oncology

News Commentary | August 27, 2021

Trillium is a developer of a novel immunotherapy solution that targets a molecule called CD47 on cancer cells. In healthy cells, CD47 plays a part in displaying a "don't‑eat‑me" signal to the immune system. Malignant cancer cells display these molecules on their surface to evade the immune system. ... Not part of subscription